Table_2_Hypomethylation of 111 Probes Predicts Poor Prognosis for Glioblastoma.XLSX (101.51 kB)

Table_2_Hypomethylation of 111 Probes Predicts Poor Prognosis for Glioblastoma.XLSX

Download (101.51 kB)
dataset
posted on 25.10.2019, 11:46 by Qi Chen, Min Zhao, Chengliang Yin, Shiyu Feng, Jian Hu, Qiang Zhang, Xiaodong Ma, Wanguo Xue, Jinlong Shi

Glioblastoma (GBM) is a complicated brain tumor with heterogeneous outcome. Identification of effective biomarkers is an urgent need for the treatment decision-making and precise evaluation of prognosis. Based on a relatively large dataset of genome-wide methylation (138 glioblastoma patients), a joint-score of 111 methyl-probes was found to be of statistical significance for prognostic evaluation. Low joint-score were significantly associated with adverse outcomes (OS: P < 0.001, PFS: P = 0.03). Multivariable analyses adjusted for known risk factors confirmed the low joint-score of 111 methyl-probes as a high risk factor. The prognostic value of the methylated joint-score was further validated in another dataset of glioblastoma patients (OS: P = 0.006). Additionally, variance analysis revealed that aberrant genetic and epigenetic alterations were significantly associated with the joint-score of those methyl-probes. In conclusion, our results supported the joint-score of 111 methyl-probes as a potential prognosticator for the precision treatment of glioblastoma.

History

Licence

Exports